By Fineline Cube 
The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)’s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.
Regulatory Timeline Summary
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Action Type | Review timeline extension |
| Product | Sarclisa (isatuximab-irfc) subcutaneous (SC) |
| Indication | Multiple myeloma (all current IV formulation indications) |
| Original Target Date | April 22, 2026 |
| Revised Target Date | July 23, 2026 |
| Extension Period | Up to three months |
| Next Steps | Final FDA decision expected by July 23, 2026 |
Product Profile & Global Status
- Current Approval: Sarclisa IV is approved in nearly 60 countries across four indications for certain patients with newly diagnosed MM and relapsed or refractory MM
- New Formulation: Sarclisa SC can be administered via both on-body injector (OBI) and manual injection, offering improved convenience over IV infusion
- European Status: Received positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) on March 26, 2026
- EU Timeline: Final European Commission decision expected in the coming months
- Therapeutic Advantage: Subcutaneous administration reduces treatment time from hours (IV) to minutes (SC), improving patient experience and clinic workflow
Market Impact Assessment
| Aspect | Analysis |
|---|---|
| Market Opportunity | U.S. multiple myeloma market valued at $8.2 billion annually with ~35,000 new cases yearly |
| Competitive Landscape | Direct competition with other anti-CD38 monoclonal antibodies; SC formulation represents significant differentiation |
| Revenue Impact | Sanofi projects peak annual sales of $1.8–2.2 billion for SC formulation if approved |
| Patient Benefit | SC administration reduces clinic visit duration from 4–6 hours (IV) to 5–10 minutes (SC injection) |
| Commercial Readiness | Sanofi has indicated commercial launch readiness within 30 days of approval |
Strategic Implications
The three-month extension suggests the FDA may require additional information or analysis, though such extensions are not uncommon for complex biologics applications. Importantly, the agency did not indicate any safety concerns or clinical hold, which would have been communicated separately.
For Sanofi, the Sarclisa SC formulation represents a critical strategic asset in maintaining market leadership in the multiple myeloma space. The subcutaneous delivery method addresses key patient and provider pain points associated with lengthy IV infusions, potentially improving treatment adherence and quality of life.
The positive CHMP opinion in Europe provides regulatory validation of the SC formulation’s safety and efficacy profile, strengthening the case for U.S. approval. Sanofi’s global strategy appears well-coordinated, with near-simultaneous regulatory submissions in major markets.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, market opportunities, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech